Monica Boros1, Septimiu Voidazan2, Cosmin Moldovan3, Rares Georgescu4, Cornelia Toganel5, Denisa Moncea6, Claudiu V Molnar7, Cristian Podoleanu8, Alexandru Eniu9, Simona Stolnicu6. 1. Department of Pathology, County Emergency Clinical Hospital Oradea, Romania. 2. Department of Medical Informatics and Biostatistics, University of Medicine and Pharmacy Targu Mures (UMPhTgM) Romania. 3. Department of Histology, UMPhTgM Romania. 4. Department of Surgery, UMPhTgM Romania. 5. Department of Oncology, UMPhTgM Romania. 6. Department of Pathology, UMPhTgM Romania. 7. Department of Obstetrics and Gynecology, UMPhTgM Romania. 8. Department of Cardiology, UMPhTgM Romania. 9. Department of Breast Tumors, Cancer Institute "I. Chiricuta" Cluj-Napoca, Romania.
Abstract
BACKGROUND: Multifocality is not listed among prognostic factors in international breast cancer guidelines. This study aims to analyze survival in multiple breast carcinomas (MFMC cc) compared to unifocal ones (UF cc), in order to assess the prognostic impact of multifocality. METHODS: The study included 460 breast carcinomas (2002-2006) with a median follow-up time of 104 months (74-134 months). We assessed mortality rates, overall survival at 5 years and 10 years in general, overall survival at 5 and 10 years in MFMC cc compared to UF cc, as well as median survival and survival rate according to age, T status and axillary lymph node status in MFMC cc compared to UF cc. We carried out a multivariate analysis in order to identify independent predictor factors for survival. RESULTS: 69/460 (15%) of cases were MFMC cc. Mortality rates were 56.5% in MFMC cc versus 45.1% (UF cc) (P = 0.08). 5-year overall survival was 55.9% in MFMC cc vs. 64.7% UF cc, and the 10-year overall survival was 34.9% MFMC cc vs. 52.7% UF cc (P = 0.27). Median survival in MFMC cc was 78 months (6.5 years), whereas in UF cc it was 126 months (10.5 years). However, in the multivariate analysis, survival was independently influenced only by tumor size and the presence of axillary lymph node metastases (P < 0.0001). CONCLUSION: Breast cancer multifocality is associated with higher general mortality rates, lower 5 and 10-year overall survival, yields a lower median survival, but it does not constitute an independent prognostic factor in multivariate analysis.
BACKGROUND: Multifocality is not listed among prognostic factors in international breast cancer guidelines. This study aims to analyze survival in multiple breast carcinomas (MFMC cc) compared to unifocal ones (UF cc), in order to assess the prognostic impact of multifocality. METHODS: The study included 460 breast carcinomas (2002-2006) with a median follow-up time of 104 months (74-134 months). We assessed mortality rates, overall survival at 5 years and 10 years in general, overall survival at 5 and 10 years in MFMC cc compared to UF cc, as well as median survival and survival rate according to age, T status and axillary lymph node status in MFMC cc compared to UF cc. We carried out a multivariate analysis in order to identify independent predictor factors for survival. RESULTS: 69/460 (15%) of cases were MFMC cc. Mortality rates were 56.5% in MFMC cc versus 45.1% (UF cc) (P = 0.08). 5-year overall survival was 55.9% in MFMC cc vs. 64.7% UF cc, and the 10-year overall survival was 34.9% MFMC cc vs. 52.7% UF cc (P = 0.27). Median survival in MFMC cc was 78 months (6.5 years), whereas in UF cc it was 126 months (10.5 years). However, in the multivariate analysis, survival was independently influenced only by tumor size and the presence of axillary lymph node metastases (P < 0.0001). CONCLUSION:Breast cancer multifocality is associated with higher general mortality rates, lower 5 and 10-year overall survival, yields a lower median survival, but it does not constitute an independent prognostic factor in multivariate analysis.
Entities:
Keywords:
Multiple breast carcinoma; prognostic factor; survival
Authors: Tibor Tot; Mária Gere; Gyula Pekár; Miklós Tarján; Syster Hofmeyer; Dan Hellberg; David Lindquist; Tony Hsiu-His Chen; Amy Ming-Fang Yen; Sherry Yueh-Hsia Chiu; László Tabár Journal: Hum Pathol Date: 2011-06-12 Impact factor: 3.466
Authors: Francisco E Vera-Badillo; Marc Napoleone; Alberto Ocana; Arnoud J Templeton; Bostjan Seruga; Mustafa Al-Mubarak; Hashem AlHashem; Ian F Tannock; Eitan Amir Journal: Breast Cancer Res Treat Date: 2014-06-14 Impact factor: 4.872
Authors: Aleodor A Andea; Tracie Wallis; Lisa A Newman; David Bouwman; Jyotirmoy Dey; Daniel W Visscher Journal: Cancer Date: 2002-03-01 Impact factor: 6.860
Authors: Julia L Oh; Mark J Dryden; Wendy A Woodward; Tse-Kuan Yu; Welela Tereffe; Eric A Strom; George H Perkins; Lavinia Middleton; Kelly K Hunt; Sharon H Giordano; Mary Jane Oswald; Delora Domain; Thomas A Buchholz Journal: J Clin Oncol Date: 2006-11-01 Impact factor: 44.544
Authors: Claudia Allemani; Pamela Minicozzi; Franco Berrino; Esther Bastiaannet; Anna Gavin; Jaume Galceran; Alberto Ameijide; Sabine Siesling; Lucia Mangone; Eva Ardanaz; Guy Hédelin; Antonio Mateos; Andrea Micheli; Milena Sant Journal: Int J Cancer Date: 2012-11-07 Impact factor: 7.396